Sugi Predict

Sugi Predict / Targets / STK17A

STK17A

Serine/threonine-protein kinase 17A · Q9UEE5 · STK17A on Sugi Atlas →

51,634 patent compounds predicted against STK17A, 32,737 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL303236 SCHEMBL303236 0.62 9/20
SCHEMBL303841 SCHEMBL303841 0.54 9/20
SCHEMBL301488 SCHEMBL301488 0.53 7/20
SCHEMBL433250 SCHEMBL433250 0.44 7/20
SCHEMBL656024 SCHEMBL656024 0.50 6/20
SCHEMBL270779 SCHEMBL270779 0.48 6/20
SCHEMBL301785 SCHEMBL301785 0.48 6/20
SCHEMBL301485 SCHEMBL301485 0.45 6/20
SCHEMBL270633 SCHEMBL270633 0.55 5/20
SCHEMBL435104 SCHEMBL435104 0.46 5/20
SCHEMBL147422 SCHEMBL147422 0.66 4/20
SCHEMBL226380 SCHEMBL226380 0.58 4/20
SCHEMBL144979 SCHEMBL144979 0.56 4/20
SCHEMBL270630 SCHEMBL270630 0.56 4/20
SCHEMBL265799 SCHEMBL265799 0.53 4/20
SCHEMBL365733 SCHEMBL365733 0.50 4/20
SCHEMBL656192 SCHEMBL656192 0.50 4/20
SCHEMBL458945 SCHEMBL458945 0.44 4/20
SCHEMBL270640 SCHEMBL270640 0.42 4/20
SCHEMBL621421 SCHEMBL621421 0.38 4/20

Clinical trials — most relevant to STK17A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis PHASE3COMPLETED
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia PHASE2COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). PHASE1ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer PHASE1WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. PHASE1ACTIVE_NOT_RECRUITING
Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a STK17A binder may also engage these)

ProteinNameSimilarity
Q9GM70 — 0.996 Q9GM70 →
Q8BG48 — 0.986 Q8BG48 →
Q91XS8 — 0.984 Q91XS8 →
STK17B Serine/threonine-protein kinase 17B 0.980 landscape →
TSSK1B Testis-specific serine/threonine-protein kinase 1 0.976 landscape →
Q6P5G0 — 0.973 Q6P5G0 →
NEK11 Serine/threonine-protein kinase Nek11 0.971 landscape →
Q28GW8 — 0.971 Q28GW8 →
D4A7V9 — 0.971 D4A7V9 →
MAPK4 Mitogen-activated protein kinase 4 0.970 landscape →
MELK Maternal embryonic leucine zipper kinase 0.970 landscape →
STK32C Serine/threonine-protein kinase 32C 0.970 landscape →
Q9QZ05 — 0.970 Q9QZ05 →
EIF2AK4 eIF-2-alpha kinase GCN2 0.970 landscape →
Q68UT7 — 0.969 Q68UT7 →
O54863 — 0.968 O54863 →
Q61846 — 0.968 Q61846 →
O70551 — 0.967 O70551 →
Q5SUV5 — 0.966 Q5SUV5 →
Q8WNU8 — 0.966 Q8WNU8 →
Q8C0Q4 — 0.966 Q8C0Q4 →
Q91821 — 0.966 Q91821 →
Q95LJ0 — 0.966 Q95LJ0 →
Q8VBY2 — 0.966 Q8VBY2 →
Q91VB2 — 0.966 Q91VB2 →
O54785 — 0.966 O54785 →
Q5HZ38 — 0.966 Q5HZ38 →
F1QGZ6 — 0.965 F1QGZ6 →
A4QNA8 — 0.965 A4QNA8 →
P97756 — 0.965 P97756 →